CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Dobutamine Hydrochloride Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2017-11-06. Latest FDA row update: 2026-10-02.
FDA lists 10 package records, with companies: Baxter Healthcare, Baxter Healthcare Corporation, Hainan Poly Pharm. Co., Ltd., Hospira, Inc., Hospira, Inc., a Pfizer Company, Slate Run Pharmaceuticals. Package NDCs: 0338-1073-02, 0338-1075-02, 0338-1077-02, 0409-0025-10, 0409-0151-10, 0409-1100-10, 0409-2344-01, 0409-2344-02, 0409-2344-88, 70436-203-80.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Baxter Healthcare | 0338-1073-02 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-1075-02 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-1077-02 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02) | Available | 2026-10-02 |
| Hainan Poly Pharm. Co., Ltd. | 70436-203-80 | Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80) | Available | 2026-09-16 |
| Hospira, Inc., a Pfizer Company | 0409-1100-10 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-0025-10 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-0151-10 | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-2344-01 | Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-2344-02 | Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-2344-88 | Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88) | Unavailable | 2026-09-22 |
Source facts
Grouped generic ingredient: Dobutamine Hydrochloride Injection · 10 package records
Therapeutic categories: Cardiovascular, Pediatric, Renal
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.